This clinical trial studies how well hyperpolarized xenon-129 magnetic resonance imaging (MRI) works for improving radiation therapy (RT) for lung cancer. Radiation induced lung injury (RILI) remains a serious side effect of RT treatment and results in symptoms of breathlessness, exercise limitations, poor lung function and an overall reduction in patient quality of life. Recent advances using MRI with inhaled xenon (Xe) gas provide a safe, repeatable method for visualizing lung function inclusive of ventilation, inflammation, and gas exchange. This trial is being done to explore using MRI scans with xenon to better image lung function, how lung function changes after radiation therapy, and to guide radiation therapy away from parts of the lung that have good function.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06925295.
Locations matching your search criteria
United States
Iowa
Iowa City
University of Iowa/Holden Comprehensive Cancer CenterStatus: Active
Contact: Sean B. Fain
PRIMARY OBJECTIVES:
I. Develop automated tools and establish a clinical workflow that incorporates Xe MRI into radiation therapy treatment planning.
II. Assess the feasibility of using Xe MRI to monitor the effect of radiation therapy on the lung.
III. Evaluate the impact of Xe MRI functionally adaptive radiation therapy on lung cancer outcomes.
OUTLINE:
Patients undergo hyperpolarized Xe-129 MRI within 10 days prior to standard of care (SOC) stereotactic body radiation therapy (SBRT), on day 5 during SOC SBRT, between days 8-11 post-SBRT treatment, and at 1 and at 6 months during follow-up. Patients also undergo blood sample collection on study and during follow-up.
After completion of study intervention, patients are followed up at 1 and 6 months.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationUniversity of Iowa/Holden Comprehensive Cancer Center
Principal InvestigatorSean B. Fain